Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2024 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

theravance biopharma inc - TBPH

TBPH

Close Chg Chg %
9.87 0.01 0.10%

Closed Market

9.88

+0.01 (0.10%)

Volume: 220.77K

Last Updated:

Dec 13, 2024, 4:00 PM EDT

Trade Now

Company Overview: theravance biopharma inc - TBPH

TBPH Key Data

Open

$9.84

 Day Range

9.74 - 10.00

52 Week Range

7.44 - 11.71

 Market Cap

$485.35M

Shares Outstanding

49.17M

 Public Float

45.34M

Beta

0.24

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$1.01

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

225.87K

  

TBPH Performance

1 Week
 
 0.00%
 
1 Month
 
 3.78%
 
3 Months
 
 21.38%
 
1 Year
 
 -10.10%
 
5 Years
 
 -54.76%
 

TBPH Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 5
Full Ratings ➔

About theravance biopharma inc - TBPH

Theravance Biopharma, Inc. is a biopharmaceutical company, which engages in the discovery, research, development, and commercialization of respiratory medicines. It operates through the U.S. and Europe geographical segments. Its products include telavancin under the VIBATIV brand, revefenacin under the TD 4208 brand, and neprilysin. The company was founded in July 2013 and is headquartered in George Town, Cayman Islands.

TBPH At a Glance

Theravance Biopharma, Inc.
901 Gateway Boulevard
South San, California 94080
Phone 1-650-808-6000 Revenue 57.42M
Industry Pharmaceuticals: Major Net Income -55,193,000.00
Sector Health Technology 2023 Sales Growth 11.837%
Fiscal Year-end 12 / 2024 Employees 99
View SEC Filings

TBPH Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 10.825
Price to Book Ratio 2.538
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -12.031
Enterprise Value to Sales 9.897
Total Debt to Enterprise Value 0.086

TBPH Efficiency

Revenue/Employee 580,040.404
Income Per Employee -557,505.051
Receivables Turnover 3.286
Total Asset Turnover 0.116

TBPH Liquidity

Current Ratio 5.392
Quick Ratio 5.392
Cash Ratio 4.136

TBPH Profitability

Gross Margin 89.461
Operating Margin -92.804
Pretax Margin -85.799
Net Margin -96.115
Return on Assets -11.157
Return on Equity -16.858
Return on Total Capital -21.054
Return on Invested Capital -14.808

TBPH Capital Structure

Total Debt to Total Equity 23.08
Total Debt to Total Capital 18.752
Total Debt to Total Assets 12.869
Long-Term Debt to Equity 21.238
Long-Term Debt to Total Capital 17.256
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Theravance Biopharma Inc - TBPH

Collapse All in section
All values USD millions. 2020 2021 2022 2023 5-year trend
Sales/Revenue
71.86M 55.31M 51.35M 57.42M
Sales Growth
-2.12% -23.03% -7.17% +11.84%
Cost of Goods Sold (COGS) incl D&A
- 7.29M 6.59M 6.05M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
6.64M 7.29M 6.59M 6.05M
Depreciation
6.64M 7.29M 6.59M 6.05M
Amortization of Intangibles
- - - -
-
COGS Growth
- - -9.57% -8.15%
-
Gross Income
- 48.02M 44.76M 51.37M
Gross Income Growth
- - -6.80% +14.78%
-
Gross Profit Margin
- +86.83% +87.17% +89.46%
2020 2021 2022 2023 5-year trend
SG&A Expense
362.97M 285.67M 123.88M 104.66M
Research & Development
257.65M 190.16M 60.79M 38.72M
Other SG&A
105.32M 95.51M 63.08M 65.94M
SGA Growth
+13.85% -21.30% -56.64% -15.51%
Other Operating Expense
- - - -
-
Unusual Expense
15.46M 20.14M 15.87M 2.74M
EBIT after Unusual Expense
(313.22M) (257.78M) (94.99M) (56.03M)
Non Operating Income/Expense
71.27M 105.10M 8.54M 9.12M
Non-Operating Interest Income
- - - -
-
Equity in Earnings of Affiliates
- - 68.44M 103.99M
-
Interest Expense
44.59M 46.89M 6.37M 2.35M
Interest Expense Growth
+39.93% +5.17% -86.42% -63.10%
Gross Interest Expense
44.59M 46.89M 6.37M 2.35M
Interest Capitalized
- - - -
-
Pretax Income
(286.54M) (199.58M) (92.81M) (49.27M)
Pretax Income Growth
-18.56% +30.35% +53.49% +46.92%
Pretax Margin
-398.76% -360.83% -180.76% -85.80%
Income Tax
(8.52M) (151.00K) 9.00K 5.92M
Income Tax - Current - Domestic
- (8.54M) (173.00K) 2.88M
Income Tax - Current - Foreign
- 25.00K 22.00K (164.00K)
Income Tax - Deferred - Domestic
- - - 3.21M
-
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - 68.44M 103.99M
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(278.02M) (199.43M) (92.82M) (55.19M)
Minority Interest Expense
- - - -
-
Net Income
(278.02M) (199.43M) (92.82M) (55.19M)
Net Income Growth
-17.58% +28.27% +53.45% +40.54%
Net Margin Growth
-386.90% -360.55% -180.78% -96.11%
Extraordinaries & Discontinued Operations
- - - (176.13M)
-
Discontinued Operations
- - - (176.13M)
-
Net Income After Extraordinaries
(278.02M) (199.43M) (268.95M) (55.19M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(278.02M) (199.43M) (268.95M) (55.19M)
EPS (Basic)
-4.4593 -2.871 -3.6547 -0.998
EPS (Basic) Growth
-4.88% +35.62% -27.30% +72.69%
Basic Shares Outstanding
62.34M 69.46M 73.59M 55.30M
EPS (Diluted)
-4.4593 -2.871 -3.6547 -0.998
EPS (Diluted) Growth
-4.88% +35.62% -27.30% +72.69%
Diluted Shares Outstanding
62.34M 69.46M 73.59M 55.30M
EBITDA
(291.11M) (230.36M) (72.53M) (47.24M)
EBITDA Growth
-18.63% +20.87% +68.51% +34.87%
EBITDA Margin
-405.13% -416.47% -141.26% -82.27%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 13.20
Number of Ratings 5 Current Quarters Estimate -0.20
FY Report Date 12 / 2024 Current Year's Estimate -1.038
Last Quarter’s Earnings -0.26 Median PE on CY Estimate N/A
Year Ago Earnings -1.00 Next Fiscal Year Estimate 0.142
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 4 2 4 5
Mean Estimate -0.20 -0.22 -1.04 0.14
High Estimates -0.14 -0.21 -0.97 1.30
Low Estimate -0.33 -0.23 -1.20 -1.02
Coefficient of Variance -43.78 -6.43 -10.51 666.38

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 2 2 2
OVERWEIGHT 0 0 0
HOLD 3 3 3
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Overweight

Insider Actions for Theravance Biopharma Inc - TBPH

Date Name Shares Transaction Value
Aug 23, 2024 Rhonda F. Farnum SVP, COMM & MEDICAL AFFAIRS 326,743 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.22 per share 2,685,827.46
Aug 23, 2024 Rick E. Winningham CHIEF EXECUTIVE OFFICER; Director 1,823,899 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.22 per share 14,992,449.78
Aug 23, 2024 Aziz Sawaf SVP & CHIEF FINANCIAL OFFICER 321,366 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.22 per share 2,641,628.52
Aug 23, 2024 Aine Miller SVP, DEV & HEAD OF IRE OFFICE 160,632 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.22 per share 1,320,395.04
Aug 23, 2024 Brett A. Grimaud SVP, GEN COUNSEL AND SECRETARY 342,613 Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $8.22 per share 2,816,278.86
May 13, 2024 Jeremy Todd Grant Director 22,305 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Dean Jonathan Mitchell Director 80,555 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Jeremy Todd Grant Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Laurie Smaldone Alsup Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Laurie Smaldone Alsup Director 64,331 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Donal M. O'Connor Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Donal M. O'Connor Director 63,555 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Susannah Gray Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Susannah Gray Director 31,488 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Deepa R. Pakianathan Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Deepa R. Pakianathan Director 47,416 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Eran Broshy Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Eran Broshy Director 80,555 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 13, 2024 Dean Jonathan Mitchell Director 23,576 Grant, award or other acq pursuant to Rule 16b-3(d) 0.00
May 6, 2024 Madison Avenue Partners LP 8,012,026 Open market or private purchase of non-derivative security Non-derivative transaction at $8.75 per share 70,105,227.50

Theravance Biopharma Inc in the News